Table 2.
Inhaler prescriptions
| Prescribed inhaler (resistance class and representative inhalers)a | Number of COPD patients, n (%)b |
|---|---|
|
| |
| R1 | 0 (0) |
| • Breezhaler® (Seebri®) | |
| • Neohaler® (Utibron®) | |
|
| |
| R2 | 32 (48) |
| • Diskus® (eg, Advair®, Serevent®) | |
| • Ellipta® (eg, Anoro®, Breo®, Incruse®, Trelegy®) | |
|
| |
| R3 | 2 (3) |
| • Pressair® (Tudorza®) | |
| • Genuair® (Aclidinium®) | |
| • Turbuhaler® (Symbicort®) | |
|
| |
| R4 | 0 (0) |
| • Turbuhaler® (Pulmicort®) | |
| • Twistihaler® (Asmanex®) | |
|
| |
| R5 | 50 (76) |
| • Handihaler® (Spiriva®) | |
Notes:
a
“R” refers to resistance class of inhaler, with R1 being the lowest resistance and R5 being the highest resistance device. See “Materials and methods” section for additional explanation.
b
Column total sums to >66 as participants could be on multiple inhalers. All values are given as n (%).